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Abstract
This review attempts to explain why consuming extra myoinositol (Ins), an essential component of membrane phospholipids, is often beneﬁcial
for patients with conditions characterised by insulin resistance, non-alcoholic fatty liver disease and endoplasmic reticulum (ER) stress. For decades
we assumed that most human diets provide an adequate Ins supply, but newer evidence suggests that increasing Ins intake ameliorates several
disorders, including polycystic ovary syndrome, gestational diabetes, metabolic syndrome, poor sperm development and retinopathy of
prematurity. Proposed explanations often suggest functional enhancement of minor facets of Ins Biology such as insulin signalling through putative
inositol-containing ‘mediators’, but offer no explanation for this selectivity. It is more likely that eating extra Ins corrects a deﬁciency of an abundant
Ins-containing cell constituent, probably phosphatidylinositol (PtdIns). Much of a cell’s PtdIns is in ER membranes, and an increase in ER
membrane synthesis, enhancing the ER’s functional capacity, is often an important part of cell responses to ER stress. This review: (a) reinterprets
historical information on Ins deﬁciency as describing a set of events involving a failure of cells adequately to adapt to ER stress; (b) proposes that in
the conditions that respond to dietary Ins there is an overstretching of Ins reserves that limits the stressed ER’s ability to make the ‘extra’ PtdIns
needed for ER membrane expansion; and (c) suggests that eating Ins supplements increases the Ins supply to Ins-deﬁcient and ER-stressed cells,
allowing them to make more PtdIns and to expand the ER membrane system and sustain ER functions.
Key words: Insulin resistance: Gestational diabetes mellitus: Polycystic ovarian syndrome: Spermatogenesis: Hypothyroidism: Non-
alcoholic fatty liver disease: Endoplasmic reticulum stress
Mammalian cells use myoinositol (Ins), a polyol that used also to
be known as vitamin B8, as the core constituent of eight Ins
phospholipids (the phosphoinositides, see Box 1), of many Ins
polyphosphates and of the glycerophosphoinositol-based (GPI)
anchors of cell surface proteins(1)§. It is quite difﬁcult to make
mammals overtly Ins-deﬁcient, except under nutritionally extreme
conditions – and then a major symptom is fat accumulation in the
liver and/or intestine. It is now commonly assumed that a normal
diet plus some endogenous synthesis usually provides us (and
other animals) with an adequate supply of Ins.
However, recent evidence suggests that consuming extra Ins
as a dietary supplement can be beneﬁcial in a variety of human
conditions, particularly those characterised by adiposity, hyper-
glycaemia and insulin resistance. These conditions include
polycystic ovary syndrome (PCOS), gestational diabetes mellitus
(GDM) and metabolic syndrome (MetS). Other possible beneﬁts
of Ins supplements include better sperm development and
motility, improved ovarian follicle and embryo development,
suppression of diabetes-induced and folate-resistant develop-
mental birth defects, and amelioration of respiratory distress
syndrome and retinopathy in premature infants (see references
2–5, for reviews). At least some of these suggested clinical ben-
eﬁts will probably become more ﬁrmly established once larger
trials have been conducted.
The most prevalent hypothesis in discussions of these exciting
observations has been that eating extra Ins might support the
formation and actions of proposed, but controversial, ‘mediators’
of insulin action that contain inositols as constituents(2,6).
§ Abbreviations for myoinositol and its derivatives: Ins is the accepted abbreviation for myoinositol, both free and in chemical combination (see http://
www.sbcs.qmul.ac.uk/iupac/cyclitol/myo.html) and is here used in: ArcIns, archaetidylinositol (the most common archaeal lipid with an Ins1P headgroup); Ins,
myoinositol; Ins1P, Ins 1-phosphate; InsP6, Ins hexakisphosphate (phytic acid); and PtdIns, phosphatidylinositol. Other inositol isomers are named or abbre-
viated individually (see below). Ins is sometimes used elsewhere as an informal abbreviation for insulin, but to avoid confusion this review will always spell out
insulin in full.
Other abbreviations: ATF6, activating transcription factor-6; CCT, CTP:phosphocholine cytidylyltransferase; CDIPT, CDP-DG inositol phosphotransferase
(≡ PIS); CDP-DG, cytidine diphosphate diacylglycerol; DCI, D-chiro-inositol; DM2, Type 2 diabetes mellitus; ER, endoplasmic reticulum; GDM, gestational
diabetes mellitus; GPI, glycerophosphoinositol; IPG, inositol phosphate glycan; IRE1, inositol-requiring enzyme-1; LPIAT1, lysoPtdIns acyltransferase-1
(≡ MBOAT7); MetS, metabolic syndrome; MIOX, myoinositol oxidase; MIPS, myoinositol 3-phosphate synthase; NAFLD, non-alcoholic fatty liver disease; PCOS,
polycystic ovarian syndrome; PERK, PKR-like ER kinase; PI3K-I, Type I phosphoinositide 3-kinase; PIS, PtdIns synthase (≡ CDIPT); PM, plasma membrane; PPIn,
polyphosphoinositide; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdOH, phosphatidate; PtdSer, phosphatidylserine; TAFLD, toxicant-
associated fatty liver disease; UPR, unfolded protein response.
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However, there is no direct evidence in support of this idea, and
none of these discussions has attempted to explain how eating
quite a lot of Ins – maybe enough to approximately double the
usual dietary intake – might selectively amplify this minor and
ill-understood facet of the Biology of Ins.
It seems more likely that the extra dietary Ins corrects a mild
systemic Ins deﬁciency that restricts the production of an abun-
dant and essential Ins-containing cell component, and the
obvious candidate is phosphatidylinositol (PtdIns), a ubiquitous
constituent of eukaryotic cell membranes. If this is correct then
the central problem becomes to discover how allowing stressed
tissues to make more PtdIns contributes to their health?
This review attempts to answer this question by:
(1) giving a snapshot of the diverse biological functions of Ins
and its derivatives;
(2) summarising the endogenously synthesised and dietary
sources of Ins;
(3) looking back to early work on Ins deﬁciency in mammals
and considering how recent work on endoplasmic
reticulum (ER) stress might help us to understand it better;
(4) summarising the evidence that Ins supplements ameliorate
several conditions in which overweight, insulin resistance,
hyperglycaemia and ER stress often coexist; and
(5) considering what mechanisms might underlie these bene-
ﬁts, and how experimentally to explore them.
These considerations lead to the conclusion that we should in
future focus our attention on understanding when and why the
ER sometimes needs to increase its production of PtdIns, the
cell’s most abundant and least studied phosphoinositide, espe-
cially when a cell’s homeostatic adjustment to ER stress demands
an increase in the rate of ER membrane synthesis – and how
limitation of the Ins supply may prejudice this response.
Ins functions and supply
During the last four decades it has been recognised that PtdIns
and its seven polyphosphorylated derivatives (the poly-
phosphoinositides (PPIn)) (see Box 1 and Fig. 1) have many
essential functions, particularly in transmembrane signalling, in
‘labelling’ the identities of membrane compartments and in
membrane trafﬁcking(1,7–10). Ins is also the precursor to a plethora
of water-soluble Ins polyphosphates, only a few of which have
understood functions(11–14). And some PtdIns is channelled to the
luminal face of the ER and incorporated into PtdIns glycan
structures that will form the ‘GPI anchors’ that tether many pro-
teins onto the external surfaces of eukaryotic cells(15,16). Alongside
these well-established functions there is 30 years of less than
conclusive evidence, to be discussed below, that insulin receptor
stimulation might activate a phospholipase that liberates inositol
phosphate glycan molecule(s) (IPGs) similar to those in GPI
anchors, and that these might serve as second messengers that
initiate some tissue responses to insulin.
Free Ins is the precursor of all of these molecules, and eukar-
yote cells get Ins from two sources. Some tissues, including brain
and kidneys, and especially testes, make Ins de novo from the
central metabolite D-glucose-6-phosphate by the sequential
actions of myoinositol 3-phosphate synthase (MIPS, encoded in
yeast by Ino1 and in humans by ISYNA1) and inositol mono-
phosphatases (InsPases, encoded in yeast by Inm1 and Inm2, and
in mammals by IMPA1 and IMPA2)(17). Secondly, speciﬁc cation/
Ins co-transporters that use Na+ or H+ as co-solutes (SMIT1/
SLC5A3, SMIT2 and HMIT/SLC2A13) harvest Ins from the gut,
take it into the tissues from the blood and recover it from the renal
glomerular ﬁltrate(18). It is commonly assumed that cells use
imported and locally made Ins in similar ways, but some obser-
vations suggest that this is not always the case(19,20).
All eukaryotic cells need an Ins supply to make PtdIns and other
Ins derivatives. It was discovered long ago that yeasts only survive
if they can make and/or import Ins; that many mammalian cell-
lines require an external Ins supply(21–23); and that mammalian
embryos which cannot make Ins develop abnormally, and the
offspring die perinatally unless they are fed Ins from birth(24).
Dietary Ins comes mainly from the PtdIns in plant and animal
foodstuffs and from the inositol polyphosphates (mainly phytic
acid; InsP6) that are abundant in many seeds. Normal
human Ins intake has been estimated to be in the range
0·25–2 g/d(25,26), but we lack precise estimates of how much of
that dietary Ins we absorb. Taking InsP6 as an example, dif-
ferent raw, cooked and processed foods contain very different
amounts, and it is not even agreed how much of the Ins in
ingested InsP6 is absorbed and in what form
(27,28). Recent
studies suggest that the gut cannot absorb intact InsP6
(29), so it is
likely that dietary InsP6 must be fully dephosphorylated before
Ins transporters can absorb it from the gut.
Given this background, it is somewhat surprising that a
growing body of information – which is discussed below and
Box 1. Inositols and inositol phospholipids in
eukaryotes: summary
The inositols are nine stereoisomeric hexahydroxy-
cyclohexanes: saturated six-carbon rings with a hydroxyl
group attached to each carbon.
Myoinositol is the predominant inositol in Nature. It is
abbreviated as Ins unless its full name is needed to
distinguish it from another inositol isomer, such as
D-chiro-inositol (DCI) (see the footnote on p. 1 for a
more detailed discussion of abbreviations).
Phosphatidylinositol (PtdIns) is much the most
abundant membrane inositol-containing
phospholipid (phosphoinositide) throughout the
cell. It is made at the cytoplasmic face of the
endoplasmic reticulum (ER), where much of it stays, by
PtdIns synthase (abbreviated as PIS or CDIPT).
Phosphoinositide kinases in the non-ER membrane com-
partments of the cells of mammals and other metazoan
eukaryotes phosphorylate some of their PtdIns to form
small amounts of seven polyphosphoinositides
(PPIn): these are three isomeric PtdIns monopho-
sphates (PtdIns3P, PtdIns4P and PtdIns5P), three
PtdIns bisphosphates (PtdIns(3,4)P2, PtdIns(3,5)P2
and PtdIns(4,5)P2) and one PtdIns trisphosphate
(PtdIns(3,4,5)P3) (see the text for references).
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summarised in Table 1 – suggests that some people get sub-
stantial health beneﬁts if they supplement their normal diets
with an extra 1–4 g of Ins/d (see references 2–5, 30–32, for
reviews). The most notable effects include an amelioration of
insulin resistance and of the related metabolic problems that
characterise PCOS, GDM, MetS and Type 2 diabetes mellitus
(DM2). The text that follows: (a) brieﬂy summarises a number
of the studies that suggest that dietary supplementation with Ins
is beneﬁcial to humans and to relevant rodent models;
(b) discusses the suggested interpretations of these studies;
(c) offers a novel interpretation of these striking ﬁndings; and
(d) suggests some experimental approaches that might help us
to understand these ﬁndings and to explain the health beneﬁts
of this inexpensive and safe nutritional supplement.
First, though, three other topics need to be brieﬂy discussed
as background: a possible reinterpretation of studies – both
older and more recent – of Ins deﬁciency in mammals and other
metazoans; the roles of various Ins derivatives in insulin sig-
nalling; and the long history of relationships between diabetes
and Ins metabolism.
Ins deﬁciency provokes the development of steatoses (and
ER stress?)
One of the most notable early observations was that dietary Ins
deﬁciency – usually in rats or gerbils – causes an Ins-reversible
fat accumulation (steatosis) in the liver and/or the intestinal
mucosa. This is most striking when withdrawal of Ins from the
diet is combined either with a diet rich in saturated fat or with
the nutrient stress of lactation (when the mother is secreting lots
of Ins into her milk for the suckling offspring)(22,26,33). Dietary
Ins supplementation sometimes also ameliorates fatty livers
caused by other metabolic stresses, such as choline deﬁ-
ciency(26). One unifying defect in these steatoses is a failure by
the Ins-deﬁcient organs efﬁciently to package and secrete the
TAG-rich lipoproteins that they make (VLDL in hepatocytes and
chylomicra in enterocytes). It has been assumed that a cellular
deﬁcit of PtdIns (and maybe of PtdIns-derived PPIn) somehow
causes these symptoms – and during Ins deﬁciency in gerbils
the PtdIns content of microsomal membranes from the intestinal
mucosa was Ins-reversibly decreased by more than one-half(34).
The underlying mechanisms of these steatoses have never
been fully understood, and by the late 1980s there was a
widespread belief that a combination of endogenous Ins
synthesis and a balanced diet provides an adequate supply of
Ins to most mammals, including humans(2,22,25,26). As a result,
most researchers turned their attention to problems that seemed
more exciting.
More recently, it has been recognised that transient or
sustained hepatic steatosis – which may or may not indicate
incipient or overt pathology – occurs in many situations of
metabolic imbalance, and this has taken centre stage under a new
name: non-alcoholic fatty liver disease (NAFLD)(35,36). A variety of
metabolic stresses can provoke and/or are closely associated with
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Fig. 1. The distribution, relative amounts and interconversions of Ins phospholipids in a generalized mammalian cell. This figure is reproduced, with
permission, from reference (10), but the legend is mine. This generalised representation of a cell summarizes the distributions and relative quantities of the various
organelles and of phosphatidylinositol (PtdIns) and the various polyphosphoinositides (PPIn) in these membrane subcompartments of eukaryote cells. The relative
areas of membrane and volumes of the various organelle compartments, and thus their relative contents of membrane lipids (including PtdIns and PPIn) will vary
substantially between cell-types. Important points to note include the following: (1) in many cells the endoplasmic reticulum (ER)/nuclear envelope continuum (the blue
reticulum in this image) usually contains a larger proportion of a cell’s membranes than other organelle systems; (2) PtdIns is made in the ER (blue) and is the only
phosphoinositide there (except maybe for transient traces of PtdIns4P); (3) PtdIns is a structural lipid that is distributed amongst all cell membranes (with less in the
mitochondrial inner membrane), and is also the substrate for synthesis and turnover of all of the compartment-specific PPIn that are in the various non-ER and non-
mitochondrial membrane systems (images of which are schematically expanded in the coloured boxes in this diagram).
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NAFLD (or TAFLD, its Toxicant-Associated equivalent(37)). These
conditions include central obesity, saturated fat feeding and viral
hepatitis, as well as toxic insults such as carbon tetrachloride
poisoning or tunicamycin inhibition of protein glycosylation.
NAFLD is common in patients with several of the conditions for
which dietary Ins supplements are now promoted, including
PCOS, GDM, MetS and DM2(36,38–40).
NAFLD is one of the commonest hepatic accompaniments of
the widespread unfolded protein response (UPR) that is evoked
in all eukaryotes by diverse stressors that cause accumulation of
incompletely folded proteins within the ER – a situation that is
known generically as ‘ER stress’. Cellular responses to ER stress,
which in the liver often include fat accumulation in hepatocytes,
are orchestrated by a complex set of coordinated controls, the
master regulators of which are three transmembrane ER pro-
teins: IRE1 (Inositol-Requiring Enzyme-1), which is present in
all eukaryotes (mammals have two: IRE1α and IRE1β); PERK
(PKR-like ER Kinase), which is restricted to metazoans; and
ATF6 (Activating Transcription Factor-6), which is also restric-
ted to metazoans (mammals have two: ATF6α and ATF6β) (see
references 41–47 and the later discussion). The ubiquitous ER
stress sensor IRE1 is a dual-activity protein kinase and endo-
ribonuclease that is central to responses provoked by diverse
stressors, but its name is a confusing hangover from the fact that
it was ﬁrst identiﬁed as a key player in the responses of yeast to
changes in external Ins supply(23,48).
Three more recent studies have shown that interfering with
the PtdIns supply in cells in other ways can provoke steatoses
that have some similarities to those seen in classical studies of
Ins deﬁciency – and which again resemble the NAFLD that is
associated with ER stress and the UPR.
First, Alb et al.(49,50) observed that reducing or abolishing rats’
ability to make PITPα, a cytosolic phospholipid exchange pro-
tein that may have a role in distributing PtdIns around cells,
provokes hepatic and intestinal steatoses similar to those pro-
voked by Ins deﬁciency(51).
Secondly, ablation in zebraﬁsh embryos of the gene encoding
PtdIns synthase (PIS, also known as CDP-diacylglycerol-inositol
phosphotransferase (CDIPT)) is lethal in 5–6days. But these PIS-
null embryos develop a fatty liver during the ﬁnal developmental
days before they die. It seems that they initially import maternally
provided PtdIns from yolk, and this allows them to develop fairly
normally for up to ~4days, but when this runs out they brieﬂy
develop an acute PtdIns deﬁciency and a fatty liver – in which a
suite of genes indicative of ER stress is turned on – and then they
die. And treatment of wild-type embryos with tunicamycin, an
inhibitor that induces ER stress by preventing the glycosylation
and correct folding of nascent proteins within the ER, produces
remarkably similar effects(52). These PIS-null embryos also
develop an intestinal mucosal pathology that partially mimics
inﬂammatory bowel disease, and which appears to be initiated by
disruption of the ER architecture in enterocytes(53).
Third, Drosophila larvae that lack or have reduced levels of
PIS or of CDP-diacylglycerol synthase (which makes the
immediate lipid precursor of PtdIns) develop only partially and
are non-viable. Many of their PtdIns-deprived tissues stay
abnormally small during their abortive development and
display abnormal intracellular accumulations of fat droplets(54).
Considered as a whole, these results suggest that: (a) the liver
and intestinal steatoses that were recognised many decades ago
as hallmarks of Ins deﬁciency were early examples of NAFLD
and its intestinal equivalent; and (b) these steatoses were
probably unrecognised consequences of the fact that a
cellular deﬁcit of Ins, and thus of PtdIns, stresses the ER and
activates the protective/homeostatic ER stress pathways. These
steatoses are particularly striking accompaniments of ER stress
in hepatocytes and enterocytes, both of which are cells whose
ER’s major tasks include the synthesis and assembly of secretory
lipoproteins, but the Drosophila observations also suggest that
the stress of PtdIns depletion may provoke fatty inﬁltration of
other tissues(54). And the Ins-reversible loss in Ins-deﬁcient
gerbils(34) of much of the enterocyte’s alkaline phosphatase – a
GPI-anchored protein that is normally made by the ER and
trafﬁcked to the exterior of the brush border membrane that
faces the gut lumen – was probably another early indication of
ER malfunction provoked by PtdIns deﬁciency.
It therefore seems likely that ER stress is widespread in the
tissues of overtly Ins-deﬁcient animals, especially in those
tissues in which cells are subjected to ﬂuctuating demands for
protein secretion and/or for ER expansion (such as the insulin-
secreting β-cells of pancreatic islets of Langerhans(55)). The ﬁnal
sections of this review will suggest a novel explanation of the
beneﬁts of dietary Ins supplements that is based on the idea:
that the ER must manufacture new membrane phospholipids,
including PtdIns, whenever a cell needs to expand its ER
membrane area as an element of its response to ER stress; that a
mild global Ins deﬁciency often interferes with this process in
metabolic diseases such as PCOS and GDM; and that Ins
supplements can relieve this deﬁciency.
Ins derivatives in insulin signalling, and the inositol
derivatives used as dietary supplements
Insulin resistance is one of the physiological features of many of
the conditions for which dietary Ins supplements are being
promoted(2); and Ins-containing molecules have at least one,
and maybe two or three, role(s) in insulin signalling.
First, the predominant mode of insulin receptor signalling
into cells is via receptor-catalysed tyrosine phosphorylation
of insulin receptor substrate-1 (IRS-1), which then activates
Type I PPIn 3-kinase (PI3K-I) (and other targets). Activated
PI3K-I converts a small amount of plasma membrane
PtdIns(4,5)P2 into PtdIns(3,4,5)P3, and this PtdIns(3,4,5)P3
recruits and regulates multiple effector proteins that control
diverse cell responses (reviewed in reference 56).
Secondly, soluble Ins-containing second messengers (or
‘mediators’) might mediate some of the actions of insulin.
A decade before insulin-stimulated PI3K-I signalling was dis-
covered, Joseph Larner’s laboratory offered evidence that
insulin-stimulated skeletal muscle makes a soluble ‘mediator’ of
insulin action(57). Subsequent work has suggested that: (a) two
such mediators (named IPG-A and IPG-B) might each control
a different subset of tissue-speciﬁc responses to insulin;
(b) each IPG contains an inositol (myoinositol in IPG-A and
D-chiro-inositol (DCI) in IPG-B); and (c) these IPGs are struc-
turally related to, and might be derived from, the GPI anchors of
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cell surface proteins(58–60). However, different laboratories have
reported very different biological effects even when working
with similar molecules(59,60), and the status of these ideas
remains uncertain after almost 40 years.
Despite these uncertainties, the idea that eating substantial
dietary supplements of Ins may augment insulin signalling
through IPGs has dominated many recent discussions(2,4,6). This
emphasis has been especially prevalent in studies that have
focussed on supplements consisting of Ins/DCI combinations,
of DCI alone or of plant-derived DCI derivatives such as pinitol
(3-O-methyl-DCI). DCI differs from myoinositol only by inver-
sion of the conﬁguration of one hydroxyl group on the inositol
ring, and DCI is normally present in mammalian blood and
urine, though at much lower concentrations than Ins(61). Much
of this DCI comes from the diet, and it still not clear whether
mammals make DCI from Ins. Ins and DCI have been reported
to be interconvertible through the action of an partially char-
acterised epimerase activity that is found in mammalian tis-
sues(58,62), but a study of intact rodents found no evidence for
their interconversion in vivo(63).
Some workers promote the virtues of dietary Ins supplements
that contain DCI(6), others are non-committal(64,65) and some cite
their disadvantages(66). Given the uncertainties about the Biology
of DCI – its interconvertibility (or not) with Ins, its role (or not) in
insulin signalling and its value (or not) as a supplement – the
remainder of this discussion will be conﬁned to exploration of
possible ways in which dietary supplements of Ins, a molecule that
has many undisputed and well-understood roles in cell function,
might help to alleviate the effects of metabolic and hormonal
imbalances. DCI and/or 3-O-methyl-DCI undoubtedly have inter-
esting biological effects, including improved diabetic control in
Type II diabetics(67), neuroprotection in diabetic mice(68), sup-
pression of inﬂammation in a mouse asthma model(69), prolonga-
tion of fruit-ﬂy lifespan(70) and very rapid activation of PKB/Akt in
cultured endothelial cells(71), but we still have little idea how these
are brought about.
Ins and diabetes
It has been known since the 19th century that excess ﬂuid intake,
including that occurring in the various types of diabetes, causes
polyuria and accelerates Ins loss into urine(72), and Daughaday
et al.(73,74) established long ago that elevated blood glucose
competes with inositol for renal reabsorbtion. They concluded
‘that the inosituria of diabetes mellitis can be attributed to
an increase in the renal clearance of inositol produced by
glycosuria’.
This focussed attention on the idea that, secondary to this
urinary loss, diabetic people and animals might suffer from an Ins
deﬁciency that would contribute to the pathogenesis of at least
some of the disease’s long-term consequences, such as neuro-
pathy, nephropathy and retinopathy. Moreover, diabetic
mothers, both human and rodent, are at increased risk of pro-
ducing offspring with neural crest-related malformations, and by
2000 a substantial body of work suggested that a modest Ins
deﬁciency might cause some of these developmental defects(75).
The second route by which the body loses Ins is through its
oxidation to glucuronate by proximal tubular myoinositol
oxidase in the kidney cortex, with the product metabolised via
the glucuronate/xylulose pathway. This route of Ins loss is also
over-active in diabetes, hypertension and obesity – and in
response to raised plasma insulin concentration, as is typically
seen in conditions involving insulin resistance(76–78).
The consequence of these adverse renal events is that any
person or animal that is diabetic and/or insulin-resistant, and so
is likely to be hyperglycaemic and/or to have elevated circu-
lating insulin, will lose Ins by one or both of these routes and
Table 1. The benefits of ins supplements in human patients and in animal models of human disease
Human study subjects Changes with dietary or other Ins supplementation
Similar benefits in
animal models? References
Men with poor sperm quality Improved sperm quality and fertility; increased sperm motility –
in vitro and with vaginal pessaries
N/A (158–165)
Women undergoing assisted reproduction to
relieve fertility problems
Improved quality of cultured IVF embryos; more pregnancies with
fewer complications (except reference (168))
Yes (66,166–171)
Women with PCOS and insulin resistance,
including some non-obese adolescents
Improved hormonal profile; more frequent ovulation and
menstruation; improved fertility; improved insulin sensitivity
N/A (6,64,65,172–179)
Pregnant women with or at risk of GDM Decreased GDM incidence (except reference (188)); improved
insulin sensitivity
Yes (*180,*181,182–188)
Women (and a few men) with high BMI and/or
at risk of MetS and/or T2D
Improvement of symptoms in a significant proportion of patients Yes (189–195)
Women at risk of adverse pregnancy outcomes
(e.g. from diabetes)
Fewer folate-resistant neural tube defects and large-for-gestational-
age babies
Yes (4,5,196)
Small pre-term infants (some of the Ins
supplements were parenteral)
Decreased incidence of respiratory distress syndrome and
retinopathy of prematurity; fewer neonatal and infant deaths
Yes (3,*197,198)
Patients with Hashimoto’s autoimmune
hypothyroidism
Fewer antibodies against thyroglobulin and thyroid peroxidase;
lower plasma TSH concentration
N/A (199,200)
GDM, gestational diabetes mellitus; IVF, in vitro fertilization; N/A, no assessment available; DCI, D-chiro-inositol.
In most of the human studies subjects consumed 1–4g of extra Ins per day, which is a readily tolerated amount (see the text), but none of these studies include information that
permit judgments about the relative merits of different quantities. Ins was taken in addition to routine folate in most studies of pregnancy (human and rodent). Some of the Ins
supplements also contained a small amount of DCI (typical Ins:DCI ratio 40:1, when present), but the available information allows no conclusions about whether DCI significantly
changed the effects of the supplements (see the text). For reasons of space, this table mainly cites recent focussed reviews, recent primary articles and/or meta-analyses –
apologies to the authors of earlier primary sources who are not cited as a result. Many of the human and animal studies have been summarised in broader
reviews(2,4,5,30–32,156,157). Bold reference numbers with asterisks (*) refer to Cochrane Collaboration systematic reviews.
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will be at increased risk of systemic Ins deﬁciency. The idea that
Ins deﬁciency may be an important feature of diabetes has
therefore become an enduring theme, though without an
agreed explanation of how it brings about its effects(2).
Conditions for which dietary Ins supplements are
therapeutic
Published reports on the effects of Ins supplements have fairly
consistently reported them to be helpful, based on evidence of
variable quality, for a substantial range of human medical con-
ditions and in animal models of these conditions. Table 1 brieﬂy
summarises the most convincing of these observations, most of
which have been discussed in detail by the reviews cited in the
table legend. The condition-speciﬁc references within the table
include more recent primary sources and also meta-analyses and
reviews of earlier studies. A few of the latter are Cochrane Col-
laboration reviews of the possible clinical beneﬁts of Ins sup-
plements: for example, in preventing or alleviating GDM and in
supporting the normal development of premature babies.
Several of the conditions that beneﬁt from Ins supplements –
including PCOS, GDM, MetS and T2D – involve related
metabolic and endocrine derangements and tend to share
physiological characteristics such as central obesity, insulin
resistance, NAFLD and tissue inﬂammation. These, in turn, are
increasingly being linked at a cellular level with the phenom-
enon of ER stress in the most affected tissues(55,79–82). Other
conditions listed in Table 1 are less obviously related, but ER
stress contributes to at least some aspects of the pathologies
involved in retinopathy(83), hypothyroidism(84), diabetic
embryopathy(85) and defective spermatogenesis(86).
The beneﬁcial studies listed in Table employed supplements
of no more than 4 g Ins per day, without any recorded adverse
effects. Moreover, some other trials, mainly in anxiety and
depressive disorders, have administered much larger doses of
Ins, typically 12–18 g/d, and have observed neither signiﬁcant
side-effects nor appreciable clinical beneﬁt(87,88).
Many of the beneﬁts of inositol supplements that are listed in
Table 1 have been observed both in human patients and in
more rigorously controlled studies of animal models. Not sur-
prisingly, few of the human studies have been large enough
and/or of sufﬁciently rigorous design to yield unambiguous
outcomes that could justify ﬁrm clinical recommendations, even
when combined in meta-analyses. As a result, the relevant
meta-analyses have often concluded with some variant of
‘Encouraging, but more studies are needed in larger and more
diverse populations’.
We also should not ignore the possibility that studies
that remain unpublished, which would be more likely to be
negative or inconclusive, might cause some publication bias.
For example, the open invitation to submit papers for a 2016/
2017 themed collection entitled ‘Inositol(s) from Bench to
Bedside in Endocrinology and Gynecology’ in the International
Journal of Endocrinology stated that ‘inositols play a pivotal
role, as drugs (my emphasis), in treating several pathologies
such as PCOS, MetS and GDM’ (https://www.hindawi.com/
journals/ije/si/828614/cfp/). The invitation solicited papers on
any aspect of inositols as dietary therapies, but did not suggest
that this collection might also have served as an appropriate
home for inconclusive or negative ﬁndings.
The animal studies have often yielded much clearer evidence
of beneﬁts of Ins feeding observed under well-controlled
laboratory conditions – for example, in decreasing the pre-
valence of neural tube defects (NTDs) in the progeny of ‘curly
tail’ mice that are genetically prone to develop folate-resistant
NTDs(5,89,90).
Might all beneﬁts of Ins supplements rely on a single
mechanism?
What cellular mechanism(s) underlie the beneﬁcial effects of
substantial Ins supplements on the conditions listed in Table 1?
Possible explanations are of two types. On the one hand, they
might involve multiple effects, with the beneﬁt to each condi-
tion having its own individual explanation, as has sometimes
been hypothesised (see in next paragraph). Alternatively, it
seems more likely that one essential, but still unidentiﬁed, set of
Ins-dependent cell functions operates less than optimally in all
of the Ins-responsive conditions, and that Ins supplements
supply extra Ins to support this function.
Several speciﬁc effects of the former type have been
postulated: these include augmentation of insulin signalling
through IPGs (see above), effects on cytoskeletal regulation(91),
phosphorylation events downstream of phospholipase C sig-
nalling(92) and inositols acting as antioxidants that protect
against the reactive oxygen species generated by cell metabo-
lism(93). Several of these would selectively implicate different
subsets of the many cell regulation processes that depend on
Ins derivatives of low abundance (such as the various PPIn, and
maybe IPGs) – but none of these reports has ever, to my
knowledge, made any attempt to explain how a modest global
Ins deﬁciency might bring about such selective actions. Indeed,
it is hard to imagine how the effects of doubling a person’s
dietary Ins intake could be targetted at improving metabolic
support for any of the various pathways that rely on, or are
regulated by, rare Ins-containing cell constituent(s) – and that
different faults in such events could contribute selectively to
different maladies.
It seems far more likely that there is a single, common,
explanation – i.e. that generous Ins supplements ensure that
cells always have enough Ins to sustain some central cell
processes that rely on an abundant Ins-containing cell
constituent. If that is the case, we must answer two questions:
(a) which abundant Ins-containing molecule has its supply
maintained by the Ins supplements; and (b) what central cell
processes are compromised by limiting the supply of this mole-
cule, especially during metabolic and endocrine imbalances?
The remainder of this review will outline an hypothesis that
attempts to answer these questions. It will: (a) suggest that
metabolically stressed tissues develop a mild Ins deﬁciency,
and that consuming extra Ins supports the increased PtdIns
biosynthesis that is needed whenever stressed ER needs to
increase its functional capacity and enlarge its membrane area;
and (b) discuss how experimentally to test this novel inter-
pretation of how extra dietary Ins improves ER function in
stressed cells.
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Ins supplements ensure a sustained supply of PtdIns – but
for what purpose?
PtdIns is the main Ins-containing membrane phospholipid of all
eukaryote cells (see below). It is much more abundant than any
of a cell’s other Ins-containing constituents and is the precursor
of most of them. Any substantial decrease in the availability of
Ins is therefore likely to diminish a cell’s PtdIns supply (see
Box 1 and the text below).
However, we know much less about speciﬁc functions of
PtdIns – assuming there are some? – than we should. This is
at least partly because the discovery of the PtdIns(4,5)P2-
dependent phosphoinositidase C signalling pathway in the
early 1980s shifted the main focus of the phosphoinositide ﬁeld
away from PtdIns (and the ER) onto PtdIns(4,5)P2 (and the
PM). And workers in this ﬁeld have since been kept fully
occupied by an unending programme of identifying the various
other PPIn and decoding their many functions (at various non-
ER sites) (as outlined in Fig. 1). As a result, it seems likely that
we have been unfairly neglecting the possibility, and maybe
likelihood, that PtdIns, a major membrane constituent, has
speciﬁc roles in membrane function and dynamics that are still
to be identiﬁed.
One useful outcome of trying to understand the beneﬁcial
effects of dietary Ins supplements may be that it makes us pose
two important questions(1,94). First, ‘Why do cells make so much
more PtdIns than they would need if PtdIns only served as a
precursor to other Ins-containing cell constituents?’ And maybe
more fundamentally, Why have phospholipids with an Ins1P
headgroup remained an essential part of the cellular apparatus
of Archaea and their Eukaryotic descendants throughout most
of the time that there has been life on Earth?
For eukaryotes like us, the most frequently offered answer
would still probably be ‘PtdIns is the essential precursor from
which all of the PPIn are made, so we need plenty of it’.
However, this answer won’t wash for archaea, because the
membranes of most of these diverse organisms contain
archaetidylinositol (ArcIns: sn-2,-3-dialkyl-glycero-1-phospho-
1D-myoinositol) or a close relative, but probably have no
phosphorylated ArcInsPn derivatives analogous to the PPIn of
eukaryotes (except for ArcIns4P as an intermediate in ArcIns
biosynthesis(95)). This surely makes it more likely that
phospholipids with an unadorned Ins1P headgroup (ArcIns in
archaea, and PtdIns in eukaryotes and a few bacteria) ﬁrst
evolved in archaea to fulﬁl some fundamental and ubiquitous
biological function(s) – which we do not yet understand –
and that eukaryote cells have both retained this (or these)
function(s) and elaborated many more?(1,94)
How much PtdIns, where in the cell is it and how is it made?
How much PtdIns do cells contain and how is it distributed
amongst their membrane systems? There are three key variables
for each type of tissue or cell – the total PtdIns concentration,
the PtdIns concentration in each organelle and the relative
membrane masses of the various organelle systems.
Mammalian cells are typically quoted as having ~10% of their
membrane phospholipid as PtdIns(96). PIS has a relatively low
afﬁnity for Ins, so the main factor that controls the rate of PtdIns
synthesis is the cytosolic free Ins concentration rather than any
regulated change in intrinsic PIS activity. PtdIns is ~12–27% of the
total phospholipid in Saccharomyces cerevisiae, with the higher
ﬁgure from yeast grown with abundant exogenous inositol; and
when yeast’s capacity for PtdIns synthesis is varied genetically it
maintains normal growth rates with as little as 4% PtdIns, but can
only grow slowly with 2% PtdIns(97).
Older estimates on mammalian tissues showed total lipid-
bound Ins concentrations of ~2–3mM in brain (ox and guinea-
pig) and liver (rat), with almost all of it in PtdIns(98,99). A recent
phosphoinositide analysis of mouse tissues found similar PtdIns
concentrations and also determined the relative concentrations
of PtdIns, of PtdInsP and PtdInsP2 (their isomers were not
resolved) and of PtdInsP3. PtdIns was again predominant: it
constituted more than 98% of the total in liver and about 92%
in brain(100).
A lipidomic analysis of membranes from cultured RAW264.7
macrophages probably offers the most authoritative information
on PtdIns concentrations in organelles: it found slightly more
PtdIns per mg membrane protein in the PM than the ER, with
considerably less in mitochondria(101). An analysis of cultured
mouse embryo ﬁbroblasts also suggested modest PtdIns
enrichment in the PM relative to the ER(102).
Many years ago I measured the distribution of PtdIns
amongst well characterised primary cell fractions from rat liver
(unpublished results). Ins was acid-liberated from dried lipid
extracts, trimethylsilylated and assayed by GLC. About half
of the PtdIns was in a microsomal fraction that was ~3-fold
enriched in the ER marker enzyme glucose 6-phosphatase and
contained about one-ﬁfth of the sedimentable 60% of the
homogenate protein. There was little PtdIns in a fraction con-
sisting largely of mitochondria (~5-fold enriched in succinate
dehydrogenase).
This information suggests that PtdIns is distributed fairly
evenly amongst a cell’s membranes, except for a considerably
lower concentration in mitochondrial inner membranes(96). In
many cells, therefore, the bulk of the PtdIns will be in the
pervasive tubuloreticular membrane network that makes up the
ER, the cell’s most extensive membrane system(103,104) (as
illustrated in Fig. 1). This is also where phosphatidate (PtdOH) –
either synthesised de novo or made by diacylglycerol kinase
from phosphoinositidase C-liberated sn-1,2-diacylglycerol – is
converted to PtdIns by a two-step pathway. First, cytidine
diphosphate diacylglycerol (CDP-DG) synthase(s) (CDS1 and/
or CDS2 in mammals) converts PtdOH to CDP-DG; and then a
single PIS (PIS/CDIPT) transfers a phosphatidyl grouping from
CDP-DG to the D-1-hydroxyl group of Ins. CDS1, CDS2 and PIS
are all integral ER membrane proteins that have their active
sites oriented towards the cytoplasm(105–107). There is growing
evidence that there are important spatial and temporal controls
over the non-homogeneous distribution of PtdIns and its
biosynthesis within the ER(108–112), but most of this discussion
will ignore these important details and consider the ER as a
single extensive membrane entity that makes PtdIns and other
membrane lipids for use by all of the cell’s membranes.
The majority of the PtdIns and PPIn molecules in many or most
mammalian cells have, for ill-understood reasons, a remarkably
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homogenous fatty acyl composition, with a C18 : 0 (stearoyl)
group on the sn-1 position of the glycerol backbone and a C20 : 4
(arachidonyl) group on the sn-2 position(113). Much of the PtdIns
that PIS makes is ﬁrst synthesised with other fatty acid comple-
ments and is then remodelled by a phospholipase/acyltransferase
cycle in which an arachidonyl-selective 2-acyltransferase
(lysoPtdIns acyltransferase-1 (LPIAT1); also known as MBOAT7)
is a major participant. LPIAT1 is essential both for mice to develop
normally and for their PtdIns to achieve its distinctive fatty acid
pairing(114). The tissues of the short-lived mice that lack LPIAT1
contain much less PtdIns than normal animals and their PtdIns
is arachidonyl-depleted. In humans, inactivating mutations in
LPIAT1/MBOAT7 give rise to a severe neurodevelopmental
syndrome characterised by intellectual disability, autism and
epilepsy(115), and humans carrying LPIAT1 allele rs641738, which
has reduced expression, have a predisposition to liver steatosis,
inﬂammation and necrosis(116–119).
It therefore seems that if mammals are to survive, be healthy
and have a normal PtdIns complement, they must be able cor-
rectly to make and to remodel a cytoplasm-facing ER pool of
PtdIns that has several functions: (a) it exports PtdIns to the
cytoplasmic leaﬂets of the cell’s other membranes, where some
cycles rapidly in and out of small metabolic pools of the cell’s
seven organelle-speciﬁc PPIn (see Box 1 and Fig. 1); (b) some of
the PtdIns ﬂips to face the ER lumen, where its fatty acid pattern
is remodelled and it is incorporated into GPI anchors that will
moor proteins to the exterior of the PM(16,120); and (c) it con-
tributes about one-tenth of the phospholipid that makes up the
lipid bilayer in the ER membrane, so we must assume that more
PtdIns must be made whenever the ER needs to be enlarged.
The UPR and ER membrane expansion: two faces of cell
responses to ER stress
The remainder of this discussion will focus on the importance of
maintaining an adequate PtdIns supply in order to support ER
membrane homeostasis. The events by which cells respond to
ER stress have been studied in exquisite detail in the yeast S.
cerevisiae, much less in cultured mammalian cells and – despite
the mounting evidence that perturbation of ER homeostasis is
an important feature of many metabolic and endocrine dis-
orders – only to a limited extent in intact mammals(45–47).
Moreover, it is increasingly being recognised that the suite of
cellular adaptive events that generally sails under the ‘ER stress’
ﬂag is simply an extreme version of a set of processes by which
cells constantly modulate their everyday functions as they adapt
to ﬂuctuating nutrient supplies, diurnal bodily rhythms, and
etc.(44,121–124).
The original yeast experiments revealed the key features of a
set of archetypal ER stress responses in which activation of a
single transmembrane ER protein (IRE1) coordinates a suite of
events in which:
(1) the complex UPR apparatus identiﬁes and disposes of aberrant
newly synthesised proteins, regulates the ER’s ongoing protein
load, and orchestrates a suite of genes whose products
enhance the ER’s luminal capacity for post-translational
processing, folding and quality control of proteins;
(2) the ER expands its membrane area, a process that demands
accelerated synthesis of phospholipids to enlarge the
membrane bilayer, and this expansion both increases the
internal volume within the ER for protein processing
and allows the membranes of the ER to accommodate
more intrinsic proteins without the lipid bilayer becoming
over-crowded; or
(3) the ER does both of the above in a coordinated manner
(reviewed in references 23,41,42).
In mammalian cells, the various elements of the ER homeo-
static responses are regulated in more complex, and sometimes
tissue-speciﬁc, ways by the interplay of ﬁve transmembrane
regulators (IRE1α, IRE1β, PERK, ATF6α and ATF6β) and the
proteins with which they functionally interact(41,42,44,125).
This discussion will focus on the membrane expansion arm
of this dichotomy, since this is the process that particularly
requires a coordinated increase in the synthesis of all of the
phospholipids, including PtdIns, that make up the lipid bilayer
of ER (and other) membranes.
The UPR, which is the ER’s response to protein misfolding
within its lumen, is mainly initiated through interactions
between any aberrant proteins that accumulate within the ER
lumen and the luminal domains of these transmembrane
regulators, especially IRE1α(41,42). It was therefore a surprise
when it was discovered that truncated transmembrane versions
of IRE1α and ATF6α that lack these luminal sensing domains
can retain their ability to initiate dramatic increases in ER
membrane biosynthesis. Occasionally this membrane expan-
sion has been assessed directly (e.g. by ﬂuorescence micro-
scopy of cells expressing tagged variants of ER-resident proteins
or by examination of thin-section electron micrographs(126–128))
but more often it is detected less directly as an increase in
the expression and/or activity of phospholipid-synthesising
enzymes – usually CTP:phosphocholine cytidylyltransferase,
the rate-limiting enzyme in phosphatidylcholine (PtdCho)
synthesis by the Kennedy pathway(23,125,129–131).
Effective inducers of such membrane expansion include
exposure to exogenous saturated fatty acids (e.g. palmitate,
C16 : 0), inhibition of the desaturation of endogenous stearate
(C18 : 0) and the over-expression of intrinsic ER proteins – or of
shortened constructs thereof that include little more than the
relevant protein’s membrane-spanning domain. It therefore
seems that the bilayer-spanning parts of the ER stress sensors
(or of their membrane-spanning intrinsic ER partner pro-
teins(132)) somehow sense an excessive degree of physical
order within the membrane bilayer – caused, for example, by
protein overcrowding or by a relatively saturated lipid
environment – and compensate by initiating synthesis of the
extra phospholipid that is needed to expand the area of ER lipid
bilayer in which the proteins reside(133–139). Remarkably, a
recent study of variant IRE1α constructs showed that major
changes can be made to the amino-acid sequence of this
protein’s transmembrane domain without substantially chan-
ging its ability to initiate this response(140).
Most efforts to explain control of the extra phospholipid
synthesis that is needed to support ER membrane expansion
have focussed, both in yeast and in mammalian cells, on
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deﬁning how these ER stress sensors stimulate extra synthesis of
the PtdCho that makes up about half of the phospholipid of
the ER’s lipid bilayer(96,125,131,141). Much less in known about the
relative importance of phosphatidylethanolamine (PtdEtn), the
second most abundant phospholipid of the ER, and of phos-
phatidylserine (PtdSer) and PtdIns, the other invariant and
essential ER membrane phospholipids, and of how their bio-
syntheses are regulated(142). But one deﬁned consequence of
genetically limiting liver cells’ ability to make either PtdEtn or
PtdSer is to provoke hepatic ER stress, especially when the
resulting PtdCho:PtdEtn ratio in the liver, which is normally
around 1·6, substantially deviates to higher or lower values(143).
Ongoing synthesis of these glycerophospholipids by the ER
must, of course, also maintain an adequate supply of these
membrane lipids to all of the cells’ other membranes, and the
complex set of distribution processes by which this is achieved
is ﬁnally beginning to be understood(141,143–145).
How might we explore the role of PtdIns in ER function in
mammalian cells and in animals?
It was yeast’s requirement for Ins as the essential PtdIns pre-
cursor that gave the name IRE1 to the prototypic ER stress
sensor of yeast. The effects of limiting the supply of exogenous
Ins to growing yeast are many, including: induction of the
expression of Ino1, and thus of endogenous Ins production; a
substantial decrease in the steady-state PtdIns concentration; a
compensatory slowing of the synthesis of other membrane
phospholipids, notably PtdCho, that are needed for membrane
maintenance and expansion; and delaying the synthesis and
trafﬁcking of the GPI anchors of proteins destined for the PM.
Overall, changing the availability of exogenous Ins inﬂuences
the expression of at least 700 yeast genes(23).
The arguments presented above suggest that the most likely
interpretation of the beneﬁcial effects of dietary Ins supplements
on various metabolic and endocrine imbalances in mammals is
that they correct an Ins deﬁciency that prevents stressed ER from
making enough PtdIns. So how can that idea be experimentally
tested – ideally both in isolated and/or cultured cells and in intact
animals? During recent decades we have been inundated by a
ﬂood of discoveries of ‘new’ and essential cell functions that rely
on molecules made from PtdIns, especially the various PPIn, and
this means that deciphering any speciﬁc functions of PtdIns will
not be easy.
Analysis of the many functions of the PPIn has been facili-
tated by the development of an ingenious armoury of speciﬁc
cell-biological tools that allow us to follow their individual
distributions and movements in intact cells and to manipulate
their concentrations enzymatically at localised intracellular
sites(7–10). However, there are not yet equivalent tools of high
speciﬁcity with which to explore the functions of PtdIns – or,
indeed, of any of the other abundant glycerophospholipids
(PtdCho, PtdEtn and PtdSer) that, in various mixtures, dominate
the core lipid bilayers of eukaryote cell membranes.
For example, we largely lack data, equivalent to those from
yeast, on the effects of changing PtdIns-synthetic capacity or the
availability of exogenous Ins on ER homeostasis in mammalian
cells. Early studies established how much exogenous Ins
various cultured cells need to support maximal growth, usually
1–3 µM, but nothing more(21). And when, more recently,
cultured cells have been radiolabelled for metabolic studies, this
has generally been done at the lowest possible – and least
costly – concentration that would kept them healthy (or at least
‘growing at an unrestrained rate under the conditions chosen
for the experiment’). For example, ~5 µM Ins was the lowest
concentration at which the HL60 promyeloid cells that we
studied grew exponentially and appeared to differentiate
normally towards neutrophils or monocytes(146).
Unfortunately, such measurements tell us nothing about
whether this would have remained an adequate Ins supply if
these cultured cells had been subjected to the sorts of sustained
demand for phospholipid biosynthesis that are seen during
extensive ER membrane proliferation events: for example, (a)
during the differentiation of immature B-lymphocytes, which
have little ER, into ER-packed and Ig-secreting plasma
cells(147,148); or (b) in response to provocations such as the
various artiﬁcial membrane stresses mentioned above. Studies
of the Ins requirements of – and the effects of Ins deprivation
on – cells undergoing such adaptations should be very infor-
mative. Might Ins restriction limit their ER expansion and pro-
voke overt ER stress, and maybe cause them to develop neutral
lipid inclusions? Might the cells even bud off inﬂammation-
provoking membrane vesicles in a manner similar to stressed
hepatocytes(149) – and/or undergo stress-induced apoptosis?
Another ER stressor is high-fat feeding, which has long been
known to potentiate the development of an Ins-responsive fatty
liver in Ins-deprived animals(22,26). When diabetes-prone mice
were fed an extreme version of a high-fat diet for 1–4 months
they developed a model of Type 2 diabetes that included tissue
Ins depletion, inosituria and insulin resistance, some of which
were partly reversed by feeding of large Ins supplements(150).
Remembering that the nutrient drain of lactation was another
potentiator of classical Ins deﬁciency-triggered liver steatosis
(see earlier)(26), one might also ask how limiting Ins supply
would inﬂuence the mammary epithelium’s pre-partum differ-
entiation in preparation for the start of lactation, a process in
which the IRE1 effector XBP1 is now known to play an essential
role(151,152). It is known that women affected by GDM, a
condition for which dietary Ins seems to be beneﬁcial (see
Table 1), tend to breastfeed less successfully than non-GDM
mothers(153). This is potentially detrimental both to the infant’s
nutrition and to the subsequent health of the mother(154). Might
continuing to take Ins supplements during lactation improve
this situation by enhancing mammary function and Ins-
enriching the mother’s milk – and thus help to sustain breast-
feeding and improve the offspring’s nutrition? And might it also
improve the mother’s chance of avoiding continued diabetes
after her pregnancy?
In a broader context, one of the ﬁrst things that might be
done in a revival of ‘old-fashioned’ studies of rats, mice or
gerbils would be to test the simple prediction that making these
animals Ins-deﬁcient would provoke many of their tissues to
display diagnostic biochemical features of ER stress, and that
these might be detectable well before the development of more
overt features such as a fatty liver.
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Finally, what do we know about the spatial organisation of the
metabolism of PtdIns within the complex and ever-changing
topology of the ER; what might its heterogenous distribution
mean; and how might it be perturbed experimentally? First, it has
recently been becoming clear that PIS, and thus PtdIns synthesis,
tends to be concentrated in some peripheral elements of the ER,
particularly where tubulovesicular elements make close contacts
with other organelles(108–111) – although it will usually still be
assumed that the new PtdIns equilibrates rapidly throughout the
cytoplasmic surface of interconnecting ER membranes.
A hint that this may not always be true comes from an intri-
guing study of the role of the nuclear envelope protein CNEP-1
(C-terminal domain Nuclear Envelope Phosphatase-1), an acti-
vator of the phosphatidate (PtdOH) phosphatase known as lipin,
in regulating nuclear membrane dynamics in Caenorhabditis
elegans embryos. As illustrated in Fig. 2, the activity of this widely
conserved regulator of substrate partitioning during glycero-
phospholipid synthesis somehow ensures that ectopic sheets of
ER do not surround the nucleus and interfere with the normal
dynamics of nuclear envelope disassembly during mitosis. The
activated PtdOH phosphatase directs biosynthetic ﬂux away from
CDP-DG and PtdIns, and so dictates that the nuclear envelope
lipid bilayer contains less PtdIns than the ’bulk’ ER. Conﬁrmation
that this relative nuclear depletion of PtdIns contributes to the
sub-compartmentation of ER membrane distribution comes from
the fact that global inhibition of PtdIns production can counteract
the accumulation of these interfering perinuclear ER structures
even when CNEP-1 is inhibited(112,155). How this happens remains
a mystery.
Conclusion
The observations discussed here suggest, rather surprisingly, that
eating some daily inositol might make a simple dietary
contribution to alleviating several common disorders. Drug com-
panies have spent many years and many fortunes trying to ﬁnd
novel and costly treatments for these conditions, and the resulting
drugs sometimes have unpleasant side-effects – whereas eating
some extra Ins, a normal and inexpensive dietary constituent,
seems benign. However, it remains worrying that well-validated
explanations for its beneﬁcial effects still elude us. Maybe the
ideas put forward here might help to get us on the right track?
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